Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag SARS-CoV-2, Influenza A/B, RSV Test Receives CE Mark

NEW YORK – Mobidiag said on Monday that it has received the CE mark for its Amplidiag Resp-4 molecular diagnostic test for the detection of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus.

The assay rapidly and simultaneously detects the viruses, which can cause similar symptoms, from one patient sample using nasopharyngeal swabs. It runs on the Mobidiag Amplidiag Easy PCR platform, which can process up to 46 samples in about three hours, Espoo, Finland-based Mobidiag said.

The firm said it is currently also developing Novodiag Resp-4, a molecular test using its Novodiag platform for the rapid, on-demand detection of SARS-CoV-2, influenza A/B virus, and RSV. That test will complement the Amplidiag Resp-4 test.

Mobidiag's Novodiag COVID-19 and Amplidiag COVID-19 PCR tests received CE-IVD marking last June.

The Scan

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.

Vitamin D From Tomatoes

According to Reuters, researchers in the UK have gene-edited tomatoes so their fruit contains vitamin D.

Cause Not Yet Spotted

NPR reports that a new study was unable to find a cause for persistent long COVID symptoms.

PNAS Papers on Central African Hunter-Gatherers, Myopia Development, Ancient Microtia Allele

In PNAS this week: population patterns among Central African hunter gatherers, effect of myopia-linked gene variant, and more.